Cradle, a Delft, The Netherlands and Zurich, Switzerland-based biotechnology company, raised $5.5M in funding.
The round was led by Index Ventures, and Kindred Capital with participation from Feike Sijbesma, and Emily Leproust.
The company intends to us the funds to continue to accelerate product development and build out its offering as the global leader in programmable biology, scale its team and support the onboarding of more design partners.
Led by CEO Stef van Grieken, Cradle gives scientists the ability to ‘reverse engineer’ proteins with the desired specific properties and has built a working platform that is already being used by a number of early stage design partners. Its self-teaching, self-improving generative machine learning models – which draw on recent advances in ‘natural language processing’ – can predict which parts of a protein’s genetic code a biologist will need to alter, improving a scientist’s chances of getting the experimental results they want.
Cradle’s operations include a ‘wet lab’, which allows the company to generate data to train their machine learning models.
FinSMEs
18/11/2022